Experts discuss how AI can bridge gaps in India’s public healthcare system

AI can help address several gaps in India’s public healthcare system. Experts highlighted earlier disease detection, remote monitoring, and tools that help frontline health workers make better decisions. These uses matter because many communities face limited diagnostic services and uneven access to care.

One example is Niramai’s breast cancer screening technology. It combines thermal imaging with AI to assess breast cancer risk through a non-invasive process. Other tools can support health workers by processing information and helping them make decisions within existing care workflows.

The technology is not automatically useful simply because it works in a laboratory. It must be clinically validated, affordable, and tested in the rural and public-health settings where it will operate. Developers must also account for incomplete data, unreliable internet, multiple languages, and different cultural contexts.

AI can support healthcare by identifying possible disease earlier and helping frontline workers make more informed decisions. Earlier detection may allow health systems to identify people who need follow-up, while decision-support tools can help workers operate in settings with limited specialist or diagnostic resources.

Niramai provides a concrete example. Its technology uses thermal imaging and AI to assess breast cancer risk through a non-invasive screening process. The company aims to reduce screening costs below Rs 50 at scale. The key mechanism is the combination of captured thermal information with an AI system that assesses risk.

These tools still need evidence before wider public-health use. They must be tested on real patients, evaluated in intended settings, and designed for local constraints. Frontline workers also need training, and the technology must fit existing workflows, languages, connectivity conditions, and government systems.

Clinical validation matters because an AI model that performs well on existing data may not work reliably in everyday healthcare. Real patients can differ from the records used to build a model. Public-health settings may also have limited diagnostic infrastructure, incomplete information, and different workflows. Evidence is needed before a tool is recommended widely.

The article describes two stages. Retrospective studies examine hospital data with known outcomes. Prospective studies test the technology in a live clinical setting without allowing its predictions to influence treatment, then compare results with established clinical findings. These steps reveal whether the tool performs beyond its development data.

Testing must also happen where the tool will actually be used, including rural areas. Decision-makers must consider clinical performance, implementation cost, and deployment feasibility together. Without that broader evidence, a promising tool may fail during rollout or be unsuitable for public-health work.

The article states that India has around 150,000 primary health centres. That figure shows why public-health deployment is much larger than building and testing a product in one hospital. A tool intended for national reach must work across a vast and varied healthcare network.

At each location, implementation involves more than installing software or equipment. Teams may need to train users, understand local requirements, adapt the product to existing workflows, and connect it with frontline healthcare infrastructure. Wadhwani AI illustrates this approach through teams embedded in state health offices across 17 states.

The scale creates a long-term challenge. A company may reach a halfway point, become disappointed, and leave if it lacks patience, perseverance, and funding. Wider adoption therefore depends on sustained collaboration with government officials and frontline systems, not just technical performance.

An AI tool depends on the conditions in which it receives information and delivers results. If internet access is inconsistent or data is incomplete, the tool may not process cases as intended. If it does not work across languages and cultural contexts, health workers may struggle to use it correctly. A laboratory success therefore may not translate into public-health value.

The article gives no single failure scenario, but it identifies the mechanism clearly: solutions must be built around real-world constraints. Developers need to understand local workflows and make tools usable within existing frontline infrastructure. Training and adaptation are also part of implementation, not optional extras.

When a tool cannot handle these conditions, it may fail to reach the communities it was meant to serve. Innovators must test feasibility and performance in intended settings, including rural areas. They also need sustained collaboration and resources to adapt the technology rather than treating system constraints as obstacles.

Technology companies cannot deliver public-health change independently because government systems already organize care, users, and infrastructure. Companies must understand both central and state systems, then fit their tools into the workflows that officials and frontline workers use. This makes implementation a shared process rather than a purely technical project.

Wadhwani AI embeds teams in state health offices across 17 states. These teams train users, learn local requirements, and adapt solutions to existing workflows. Each application must also connect with frontline healthcare infrastructure. Government officials implement the solutions, while innovators help make them workable.

This partnership improves the chance that a tool will be used beyond a pilot. It also helps companies respond to differences between states and local settings. The article stresses that reaching around 150,000 primary health centres demands patience, perseverance, financial resources, and deep commitment from all participants.

Artificial intelligence refers to computer systems that identify patterns in data and use them to produce predictions, classifications, or assessments. In healthcare, this can help flag disease risk or support decisions. The article focuses on AI models that may assist screening and frontline workers, but pattern-finding alone does not prove that a model is dependable.

For example, Niramai uses thermal imaging and AI to assess breast cancer risk. The model may identify patterns linked with risk, yet clinicians and health systems still need evidence that its assessments work on real people. Retrospective and prospective studies provide different forms of testing, while comparison with established clinical findings checks performance.

Human oversight remains important because healthcare decisions affect patients and depend on context. A model must be evaluated for clinical performance, cost, feasibility, and reliability in intended settings. This is established healthcare practice, while the article specifically emphasizes validation, real-world constraints, and long-term implementation.